These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 11303035

  • 1. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ, Murphy RT, Dooley M, Foley JB, Fitzgerald DJ.
    J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
    [Abstract] [Full Text] [Related]

  • 2. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 3. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
    Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J.
    Clin Pharmacol Ther; 2002 Mar; 71(3):186-95. PubMed ID: 11907493
    [Abstract] [Full Text] [Related]

  • 5. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD.
    Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
    [Abstract] [Full Text] [Related]

  • 6. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF.
    J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
    [Abstract] [Full Text] [Related]

  • 7. Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction.
    Desch S, Siegemund A, Scholz U, Adam N, Eitel I, de Waha S, Fürnau G, Lurz P, Wetzel S, Schuler G, Thiele H.
    Clin Res Cardiol; 2012 Feb; 101(2):117-24. PubMed ID: 22015616
    [Abstract] [Full Text] [Related]

  • 8. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G, Hafner T, Siller-Matula JM, Francesconi M, Grohs K, Wilhelm E, Podczeck-Schweighofer A.
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [Abstract] [Full Text] [Related]

  • 9. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
    Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D.
    Circulation; 1999 May 04; 99(17):2231-8. PubMed ID: 10226086
    [Abstract] [Full Text] [Related]

  • 10. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM, Buckland RJ, Holgate CE, Storey RF.
    Platelets; 2005 Nov 04; 16(7):398-407. PubMed ID: 16236601
    [Abstract] [Full Text] [Related]

  • 11. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.
    Thromb Haemost; 1998 Dec 04; 80(6):994-1001. PubMed ID: 9869173
    [Abstract] [Full Text] [Related]

  • 12. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
    Quinn MJ, Cox D, Foley JB, Fitzgerald DJ.
    J Pharmacol Exp Ther; 2000 Nov 04; 295(2):670-6. PubMed ID: 11046104
    [Abstract] [Full Text] [Related]

  • 13. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A, Voss R.
    Thromb Res; 2006 Nov 04; 117(3):307-14. PubMed ID: 15894353
    [Abstract] [Full Text] [Related]

  • 14. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
    Zahn R, Haubelt H, Bechtloff S, Schneider S, Frilling B, Rustige J, Marsalek P, Seidl K, Senges J, Hellstern P.
    Herz; 2003 Aug 04; 28(5):445-52. PubMed ID: 12928744
    [Abstract] [Full Text] [Related]

  • 15. Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty.
    Mazurov AV, Pevzner DV, Antonova OA, Byzova TV, Khaspekova SG, Semenov AV, Vlasik TN, Samko AN, Staroverov II, Ruda MY.
    Platelets; 2002 Dec 04; 13(8):465-77. PubMed ID: 12487780
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE, Gupta R, Rajendran S, Luu J, French JK, Juergens CP.
    Cardiovasc Ther; 2016 Oct 04; 34(5):330-6. PubMed ID: 27327862
    [Abstract] [Full Text] [Related]

  • 17. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty.
    Mager DE, Mascelli MA, Kleiman NS, Fitzgerald DJ, Abernethy DR.
    J Pharmacol Exp Ther; 2003 Dec 04; 307(3):969-76. PubMed ID: 14534354
    [Abstract] [Full Text] [Related]

  • 18. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
    Chakrabarti S, Clutton P, Varghese S, Cox D, Mascelli MA, Freedman JE.
    Thromb Res; 2004 Dec 04; 113(3-4):225-33. PubMed ID: 15140587
    [Abstract] [Full Text] [Related]

  • 19. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA, Worley S, Veriabo NJ, Lance ET, Mack S, Schaible T, Weisman HF, Jordan RE.
    Circulation; 1997 Dec 02; 96(11):3860-6. PubMed ID: 9403608
    [Abstract] [Full Text] [Related]

  • 20. Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab.
    Graff J, Andries D, Elsner M, Westrup D, Bassus S, Franz N, Klinkhardt U, Harder S.
    Br J Clin Pharmacol; 2001 Jun 02; 51(6):577-82. PubMed ID: 11422017
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.